Bartosz Sokół

Dr. Bartosz Sokół

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SPSzymon Plewa
Szymon Plewa
KPKarolina Poplawska-Domaszewicz
Karolina Poplawska-Domaszewicz
JFJolanta Florczak-Wyspianska
Jolanta Florczak-Wyspianska
AKAgnieszka Klupczynska-Gabryszak
Agnieszka Klupczynska-Gabryszak
BSBartosz Sokół
Bartosz Sokół
JMJan Matysiak
Jan Matysiak
Parkinson’s disease (PD) is a major public health problem. Since currently there are no reliable diagnostic tools to reveal the early steps of PD, new methods should be developed, including those searching the variations in human metabolome. Alterations in human metabolites could help to establish an earlier and more accurate diagnosis. The presented research shows a targeted metabolomics study of both of the serum and CSF from PD patients, atypical parkinsonian disorders (APDs) patients, and the control. The use of the LC-MS/MS system enabled to quantitate 144 analytes in the serum and 51 in the CSF. This information about the concentration enabled for selection of the metabolites useful for differentiation between the studied group of patients, which should be further evaluated as candidates for markers of screening and differential diagnosis of PD and APDs. Among them, the four compounds observed to be altered in both the serum and CSF seem to be the most important: tyrosine, putrescine, trans-4-hydroxyproline, and total dimethylarginine. Furthermore, we indicated the metabolic pathways potentially related to neurodegeneration processes. Our studies present evidence that the proline metabolism might be related to neurodegeneration processes underlying PD and APDs. Further studies on the proposed metabolites and founded metabolic pathways may significantly contribute to understanding the molecular background of PD and improving the diagnostics and treatment in the future.

1 August 2015 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
BSBartosz Sokół
Bartosz Sokół
AWAnna Woźniak
Anna Woźniak
RJRoman Jankowski
Roman Jankowski
Stefan  JurgaStefan Jurga
Stefan Jurga
NWNorbert Wąsik
Norbert Wąsik
BGBartosz Grzeskowiak
Bartosz Grzeskowiak

28 August 2017 in Frontiers in Neurology
Verified
Journal Article
Open access
BSBartosz Sokół
Bartosz Sokół
BUBartosz Urbaniak
Bartosz Urbaniak
NWNorbert Wąsik
Norbert Wąsik
SPSzymon Plewa
Szymon Plewa
AKAgnieszka Klupczynska-Gabryszak
Agnieszka Klupczynska-Gabryszak
ZKZenon J. Kokot
Zenon J. Kokot
Background: The authors are aware of only one article investigating amino acid concentrations in cerebrospinal fluid (CSF) in patients with ruptured intracranial aneurysms, and this was published 31 years ago. Since then, both management of subarachnoid haemorrhage (SAH) and amino acid assay techniques have seen radical alterations, yet the pathophysiology of SAH remains unclear. Objective: To analyse the pattern of concentrations of amino acids and related compounds in patients with different outcomes following aneurysmal SAH. Methods: 49 CSF samples were collected from 23 patients on days 0-3, 5 and 10 post-SAH. Concentrations of 33 amino acids and related compounds were assayed by liquid chromatography tandem-mass spectrometry in patients with good (Glasgow Outcome Scale 1-3) and poor (Glasgow Outcome Scale 4-5) outcome. Results: Of the 33 compounds assayed, only hydroxyproline and 3-aminoisobutyric acid appeared not to increase significantly following SAH. In poor outcome patients we found significantly higher concentrations of aspartic acid (p=0.038), glutamic acid (p=0.038) and seven other compounds on day 0-3 post-SAH; glutamic acid (p=0.041) on day 5 post-SAH, and 2-aminoadipic acid (p=0.033) on day 10 post-SAH. The most significant correlation with Glasgow outcome scale at three months was found for aminoadipic acid on day 10 post-SAH (cc= -0.81). Conclusions: Aneurysmal rupture leads to a generalised increase of amino acids and related compounds in CSF. The patterns differ between good and poor outcome cases. Increased excitatory amino acids are strongly indicative of poor outcome.

25 May 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BSBartosz Sokół
Bartosz Sokół
NWNorbert Wąsik
Norbert Wąsik
RJRoman Jankowski
Roman Jankowski
MHMarcin Holysz
Marcin Holysz
BWBarbara Więckowska
Barbara Więckowska
PJPaweł Jagodziński
Paweł Jagodziński
Toll-like receptor (TLR) signalling begins early in subarachnoid haemorrhage (SAH), and plays a key role in inflammation following cerebral aneurysm rupture. Available studies suggest significance of endogenous first-line blockers of a TLR pathway—soluble TLR2 and 4. Eighteen patients with SAH and acute hydrocephalus underwent endovascular coiling and ventriculostomy; sTLR2 and 4 levels were assayed in cerebrospinal fluid (CSF) collected on post-SAH days 0–3, 5, and 10–12. Release kinetics were defined. CSF levels of sTLR2 and 4 were compared with a control group and correlated with the clinical status on admission, the findings on imaging, the degree of systemic inflammation and the outcome following treatment. None of study group showed detectable levels of sTLR2 and 4 on post-SAH day 0–3. 13 patients showed increased levels in subsequent samples. In five SAH patients sTLR2 and 4 levels remained undetectable; no distinctive features of this group were found. On post-SAH day 5 the strongest correlation was found between sTLR2 level and haemoglobin level on admission (cc = -0.498, P = 0.037). On post-SAH day 10–12 the strongest correlation was revealed between sTLR2 and treatment outcome (cc = -0.501, P = 0.076). Remaining correlations with treatment outcome, status at admission, imaging findings and inflammatory markers on post-SAH day 5 and 10–12 were negligible or low (-0.5 ≤ cc ≤ 0.5). In the majority of cases, rupture of a cerebral aneurysm leads to delayed release of soluble TLR forms into CSF. sTLR2 and 4 seem to have minor role in human post-SAH inflammation due to delayed release kinetics and low levels of these protein.

1 December 2018 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
BSBartosz Sokół
Bartosz Sokół
NWNorbert Wąsik
Norbert Wąsik
BWBarbara Więckowska
Barbara Więckowska
WMWitold Mańko
Witold Mańko
RJRobert Juszkat
Robert Juszkat
RJRoman Jankowski
Roman Jankowski

Verified
Journal Article
Open access
PDF file
MWMałgorzata Wojtkowska
Małgorzata Wojtkowska
NKNatalia Paulina Karczewska
Natalia Paulina Karczewska
KPKlaudia Pacewicz
Klaudia Pacewicz
APAndrzej Pacak
Andrzej Pacak
PKPiotr Kopeć
Piotr Kopeć
BSBartosz Sokół
Bartosz Sokół
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders globally and leads to an excessive loss of dopaminergic neurons in the substantia nigra of the brain. Circulating cell-free DNA (ccf-DNA) are double-stranded DNA fragments of different sizes and origins that are released into the serum and cerebrospinal fluid (CSF) due to cell death (i.e., necrosis and apoptosis) or are actively released by viable cells via exocytosis and NETosis. Using droplet digital polymerase chain reaction (ddPCR), we comprehensively analyzed and distinguished circulating cell-free mitochondrial DNA (ccf mtDNA) and circulating cell-free nuclear DNA (ccfDNA) in the serum and CSF of PD and control patients. The quantitative analysis of serum ccf-DNA in PD patients demonstrated a significant increase in ccf mtDNA and ccfDNA compared to that in healthy control patients and a significantly higher copy of ccf mtDNA when compared to ccfDNA. Next, the serum ccf mtDNA levels significantly increased in male PD patients compared to those in healthy male controls. Furthermore, CSF ccf mtDNA in PD patients increased significantly compared to ccfDNA, and ccf mtDNA decreased in PD patients more than it did in healthy controls. These decreases were not statistically significant but were in agreement with previous data. Interestingly, ccf mtDNA increased in healthy control patients in both serum and CSF as compared to ccfDNA. The small sample size of serum and CSF were the main limitations of this study. To the best of our knowledge, this is the first comprehensive study on serum and CSF of PD patients using ddPCR to indicate the distribution of the copy number of ccf mtDNA as well as ccfDNA. If validated, we suggest that ccf mtDNA has greater potential than ccfDNA to lead the development of novel treatments for PD patients.